Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2016', provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects
- The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ventilator Associated Pneumonia (VAP) Overview 9
Therapeutics Development 10
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 10
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 12
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 18
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 19
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 20
Achaogen Inc. 20
Adenium Biotech ApS 21
Aridis Pharmaceuticals LLC 22
AstraZeneca Plc 23
Cardeas Pharma Corp. 24
MedImmune, LLC 25
Meiji Seika Pharma Co., Ltd. 26
Merck & Co., Inc. 27
Motif Bio Plc 28
Nabriva Therapeutics AG 29
Savara Inc. 30
Tetraphase Pharmaceuticals Inc. 31
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(amikacin + fosfomycin) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(avibactam + ceftazidime) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(cilastatin sodium + imipenem + relebactam) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AA-139 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Aerucin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
arbekacin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eravacycline - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
fosfomycin tromethamine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
iclaprim mesylate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
lefamulin acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MEDI-4893 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nu-2 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Panaecin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
panobacumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
plazomicin sulfate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Qn-2251 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
tedizolid phosphate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
tosatoxumab - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
vancomycin hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 79
Ventilator Associated Pneumonia (VAP) - Dormant Projects 104
Ventilator Associated Pneumonia (VAP) - Discontinued Products 105
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 106
Featured News & Press Releases 106
Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 106
Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured 106
Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 106
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 108
Disclaimer 109

List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2016 10
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc., H1 2016 20
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2016 21
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 22
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H1 2016 23
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H1 2016 24
Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune, LLC, H1 2016 25
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 26
Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co., Inc., H1 2016 27
Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H1 2016 28
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H1 2016 29
Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H1 2016 30
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H1 2016 79
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2016 104
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2016 105